1201924-32-4

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-
• Synonyms: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-;6-Chloro-3-methyl-pyridine-2-carboxylic acid
• CAS NO: 1201924-32-4
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 172
• Mol File: 1201924-32-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 333.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.390±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.93±0.32(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(1201924-32-4)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 6-chloro-3-methyl-(1201924-32-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1201924-32-4(Hazardous Substances Data)

Usage

Description

2-Pyridinecarboxylic acid, 6-chloro-3-methylis a disubstituted pyridinecarboxylic acid that possesses unique structural features and functional groups. It is characterized by the presence of a chloro substituent at the 6th position and a methyl group at the 3rd position on the pyridine ring, along with a carboxylic acid group at the 2nd position. 2-Pyridinecarboxylic acid, 6-chloro-3-methylis known for its potential to form various biologically active molecules, making it a valuable intermediate in the synthesis of pharmaceuticals and other bioactive compounds.

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxylic acid, 6-chloro-3-methylis used as a key intermediate in the synthesis of biologically active compounds for the pharmaceutical industry. Its unique structure allows for the development of molecules with specific binding affinities and selectivity, which can be crucial for the treatment of various diseases and conditions.
Used as Inhibitors of Janus Kinases:
In the field of medicinal chemistry, 2-Pyridinecarboxylic acid, 6-chloro-3-methylis utilized as a precursor for the preparation of inhibitors targeting Janus kinases (JAKs). These enzymes play a significant role in cell signaling pathways and are implicated in various inflammatory and autoimmune diseases. By inhibiting JAKs, the compound can potentially help in managing conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Used as Inhibitors of PDK1:
Another application of 2-Pyridinecarboxylic acid, 6-chloro-3-methylis in the development of inhibitors for 3-phosphoinositide-dependent protein kinase-1 (PDK1). PDK1 is a key regulatory enzyme involved in various cellular processes, including cell survival, growth, and metabolism. Inhibition of PDK1 can have therapeutic potential in treating cancer and other diseases where abnormal cell growth and survival are observed.

InChI:InChI=1S/C7H6ClNO2/c1-4-2-3-5(8)9-6(4)7(10)11/h2-3H,1H3,(H,10,11)

Upstream product

• 20970-75-6 2-cyano-3-methylpyridine 
• 159727-88-5 3-methyl-1-oxido-pyridin-1-ium-2-carbonitrile 
• 1201924-31-3 6-chloro-3-methyl-pyridine-2-carbonitrile 
• 878207-92-2 methyl 6-chloro-3-methyl-pyridine-2-carboxylate 
• 59718-84-2 3-methyl-pyridine-2-carboxylic acid methyl ester 
• 878207-91-1 methyl 3-methyl-1-oxido-pyridin-1-ium-2-carboxylate 
• 58997-10-7 ethyl 3-methylpyridine-2-carboxylate 
• 4021-07-2 3-methyl-pyridine-2-carboxylic acid 
• 850864-53-8 ethyl 3-methyl-1-oxido-pyridin-1-ium-2-carboxylate 
• 850864-54-9 ethyl 6-chloro-3-methyl-pyridine-2-carboxylate 

Downstream Products

• 878207-92-2 methyl 6-chloro-3-methyl-pyridine-2-carboxylate 
• 1201924-34-6 methyl 3-(bromomethyl)-6-chloropicolinate 
• 1529760-72-2 methyl 4-[(6-chloro-3-methyl-pyridine-2-carbonyl)amino]-3,5-dimethyl-benzoate 
• 930303-55-2 2-chloro-1,7-naphthyridin-8(7H)-one 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

DIMETHYLBENZOIC ACID COMPOUNDS

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.